Kyorin Pharmaceutical Co (TSE:4569) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4569 Kyorin Pharmaceutical Co Ltd TSE:4569
74 GF Score
Price 円1,170.00
GF Value 円1,583.07
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Kyorin Pharmaceutical Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

TSE:4569
74GF Score
Kyorin Pharmaceutical Co Ltd TSE:4569
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?

Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued. The current stock price of 円1,170.00 is trading 26.1% below its estimated GF Value™ of 円1,583.07. GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4569:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: 円1,583.07 vs. price of 円1,170.00 (26.1% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyorin Pharmaceutical Co Business Description

Address 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score

Get the complete analysis for TSE:4569

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,170.00
Price
円1,583.07
GF Value